MedTrace Logo

A D1 Agonist For Working Memory

NCT02507206 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 120

Last updated 2018-04-09

No results posted yet for this study

Summary

The purpose of the study is to examine the effects of the administration of a drug called DAR-0100A on attention and memory in persons with schizotypal personality disorder (SPD). DAR-0100A has not been FDA approved, however in recent studies has been used to treat cognitive deficits, meaning problems in the way you organize your thinking, in people diagnosed with schizophrenia.

Many people who carry a diagnosis of schizotypal personality disorder have trouble with attention and memory. Increasing the presence of a brain chemical called dopamine has been found to help people with schizophrenia with their attention and memory problems. This study will investigate whether the same is true for people with schizotypal personality disorder by using DAR-0100A, a drug that has been shown to help with the cognitive deficits of people with Parkinson's disease by increasing dopamine effects. Information collected in this experiment may lead to a better understanding of the brain mechanisms involved in schizotypal personality disorder and improve treatments for the psychological problems associated with this condition.

Conditions

  • Schizotypal Personality Disorder
  • SPD

Interventions

DRUG

DAR 0-100A

15 mg DAR 0100A is dissolved in 150 cc NS administered over 30 minutes intravenously.

DRUG

Placebo

15 mg DAR placebo is dissolved in 150 cc NS administered over 30 minutes intravenously.

Sponsors & Collaborators

  • New York State Psychiatric Institute

    collaborator OTHER

  • National Institute of Mental Health (NIMH)

    collaborator NIH

  • Antonia New

    lead OTHER

Principal Investigators

  • Antonia S. New, MD · Icahn School of Medicine at Mount Sinai

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2013-04-30
Primary Completion
2018-01-12
Completion
2018-01-12

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02507206 on ClinicalTrials.gov